ライフサイエンスコーパス: rhIL-11

1 rhIL-11 alone or in combination with rhG-CSF resulted in

2 rhIL-11 alone was administered by a daily subcutaneous i

3 rhIL-11 alone was associated with a mean 76%, 93%, 108%,

4 rhIL-11 also inhibits production of several immunostimul

5 rhIL-11 ameliorated structural manifestations of radiati

6 rhIL-11 is safe and effective in reducing treatment-asso

7 rhIL-11 pretreatment of thioglycollate-elicited peritone

8 rhIL-11 was partially protective (4 of 10, 40% survival)

9 rhIL-11-treated animals (150 micrograms/kg intravenously

10 controlled trial of recombinant human IL-11 (rhIL-11) in 93 patients with cancer who had already been

11 Recombinant human IL-11 (rhIL-11) is an anti-inflammatory cytokine that can reduc

12 Recombinant human IL-11 (rhIL-11; 2 mg/kg/d) or vehicle was given through the ile

13 Recombinant human interleukin 11 (rhIL-11) is a cytokine with thrombocytopoietic activity

14 Recombinant human interleukin-11 (rhIL-11) has recently become available clinically as a p

15 I trial of recombinant human interleukin-11 (rhIL-11) in women with breast cancer.

16 Recombinant human interleukin-11 (rhIL-11) is a multifunctional cytokine that can reduce i

17 tential of recombinant human interleukin-11 (rhIL-11) was tested in a neutropenic rat model that mimi

18 Recombinant human interleukin-11 (rhIL-11), a glycoprotein 130 (gp130)-signaling cytokine

19 termine if recombinant human interleukin-11 (rhIL-11), known to downregulate several inflammatory mod

20 cytokine, recombinant human interleukin-11 (rhIL-11), on megakaryocytopoiesis in vitro.

21 ctivity of recombinant human interleukin-11 (rhIL-11, [Neumega, Cambridge, MA]) in patients with cirr

22 safety of recombinant human interleukin-11 (rhIL-11; Neumega, Genetics Institute, Inc, Cambridge, MA

23 rhosis and thrombocytopenia, we administered rhIL-11 at 50 microg/kg/d subcutaneously to 10 patients

24 ase in soluble P-selectin was observed after rhIL-11 treatment, indicating that platelet activation i

25 0% survival); the combination of rhG-CSF and rhIL-11 resulted in a survival rate of 80% (16 of 20; P

26 7 days; the combination of both rhG-CSF and rhIL-11; or saline control.

27 TNF-alpha levels were not different between rhIL-11-treated animals and the control group; however,

28 The LD50 was not affected by rhIL-11 but was 10-fold lower in the anti-TNF MAb group

29 Amelioration of disease by rhIL-11, as shown by reduced keratinocyte proliferation

30 orubicin (60 mg/m2) chemotherapy followed by rhIL-11 at their assigned dose (days 3 through 14).

31 erved, which suggests that the regulation by rhIL-11 occurs after transcription.

32 mast cell numbers were partially restored by rhIL-11.

33 hepatic and splenic tissue was unchanged by rhIL-11 but was significantly increased by TNF or IL-11

34 The half-life of infused VWF is unchanged by rhIL-11 in homozygous VWD dogs.

35 In conclusion, rhIL-11 can improve platelet counts in patients with ear

36 A multifunctional cytokine, rhIL-11, modulates macrophage and type I T-lymphocyte fu

37 ded treatment with placebo or 50 microg/kg/d rhIL-11 subcutaneously for 10 or 17 days after the first

38 utive days with subcutaneous 250 microg/kg/d rhIL-11.

39 kg subcutaneously every 24 hours for 7 days; rhIL-11 at 200 micrograms/kg subcutaneously every 24 hou

40 eria monocytogenes after receiving high-dose rhIL-11, anti-tumor necrosis factor (TNF) monoclonal ant

41 WD) and normal dogs were treated with either rhIL-11 (50 microg/kg/d subcutaneously x 7 days) or DDAV

42 ulations in the liver was observed following rhIL-11 treatment.

43 rhosis and these patients could benefit from rhIL-11 treatment.

44 Furthermore, rhIL-11-treatment of LPS macrophages resulted in signifi

45 Importantly, rhIL-11 treatment produced a 2.5- to 11-fold increase in

46 The survival rate in rhIL-11-treated animals was 40% (19/47), whereas it was

47 IV) bolus injection of 250 or 1000 microg/kg rhIL-11.

48 In the DU-145 prostate carcinoma cell line, rhIL-11 stimulates a transient and dose-dependent increa

49 Importantly, in vWf-deficient mice, rhIL-11 also induced a significant increase in FVIII ind

50 iple inflammatory conditions, the ability of rhIL-11 to inhibit the binding activity of this pleiotro

51 translocation correlated with the ability of rhIL-11 to maintain or increase protein levels of the in

52 These results indicate that the ability of rhIL-11 to modulate the inflammatory response is not dep

53 recombinant human (rh)IL-11, the ability of rhIL-11 to reduce serum levels of inflammatory mediators

54 elucidate the anti-inflammatory activity of rhIL-11 in vivo, the effect of rhIL-11 in a model of Con

55 ggest that the anti-inflammatory activity of rhIL-11 is mediated in part by inhibition of NF-kappaB-d

56 The activity of rhIL-11 was not mediated through induction of IL-10, IL-

57 These data show that local administration of rhIL-11 ameliorates early intestinal radiation injury an

58 The administration of rhIL-11 was not associated with fever.

59 Analysis of rhIL-11 effects on transcription factors that activate p

60 e of 9 (60%) of 15, while the combination of rhIL-11 and ciprofloxacin resulted in 100% survival (15/

61 ese results indicate that the combination of rhIL-11 and rhG-CSF is additive as a treatment strategy

62 We are testing subcutaneous delivery of rhIL-11 to patients with psoriasis in a phase 1 open-lab

63 on injury and support further development of rhIL-11 to reduce manifestations of intestinal radiation

64 Administration of a single dose of rhIL-11 before Con-A administration reduced centrilobula

65 toprotective, we have examined the effect of rhIL-11 compared with transforming growth factor (TGF)-b

66 y activity of rhIL-11 in vivo, the effect of rhIL-11 in a model of Concanavalin A (Con-A)-induced T-c

67 id not block the antiproliferative effect of rhIL-11 indicating that the rhIL-11 activity was not med

68 Consistent with the lack of effect of rhIL-11 on platelets in vivo, IL-11 receptor alpha chain

69 Surprisingly, no effect of rhIL-11 on vWf or FVIII messenger RNA was observed, whic

70 The thrombocytopoietic effect of rhIL-11 seems to be both dose and schedule dependent and

71 The effects of rhIL-11 on the production of inflammatory mediators in v

72 that a clinical evaluation of the effects of rhIL-11-induced vWf/FVIII elevation in maintaining hemos

73 tion therapy with recombinant human forms of rhIL-11 and rhG-CSF was studied in a neutropenic rat mod

74 Subcutaneous injection of rhIL-11 generally was well tolerated.

75 dy indicates that subcutaneous injections of rhIL-11 were able to slow the progression of attachment

76 ections of either 15, 30, or 80 microg/kg of rhIL-11 in saline buffer twice a week.

77 women were accrued to five dosage levels of rhIL-11 (10, 25, 50, 75, and 100 micrograms/kg/d).

78 NF-kappaB binding activity in the nucleus of rhIL-11-treated peritoneal macrophages was significantly

79 The presence of rhIL-11 receptor alpha chain protein in the cells was es

80 determined that MKs can be direct targets of rhIL-11 by showing the expression of functional IL-11 re

81 o investigate the safety and tolerability of rhIL-11 in patients with Crohn's disease and to explore

82 ency of regimen-related toxicity, the use of rhIL-11 in patients with cirrhosis should be administere

83 provides a rationale for the clinical use of rhIL-11 to preserve the integrity of the gastrointestina

84 ee fibrin clot medium with rhIL-11, IL-3, or rhIL-11 plus IL-3 and an antibody that neutralizes human

85 tients were randomized to receive placebo or rhIL-11 at 50 or 25 micrograms/kg subcutaneously once da

86 andomized to receive subcutaneous placebo or rhIL-11 at doses of 5, 16, or 40 microgram.kg-1.wk-1 giv

87 In the ITT population, rhIL-11 significantly decreased the requirement for plat

88 usions; 27 of 40 (68%) patients who received rhIL-11 did not require transfusions, compared with 15 o

89 t counts were found among patients receiving rhIL-11 40 microgram.kg-1.wk-1 as 2 or 5 weekly doses an

90 We conclude that rhIL-11 has thrombopoietic activity at all doses studied

91 These data indicate that rhIL-11 acts directly on MKs and MK progenitors but not

92 Taken together, these results indicate that rhIL-11 ameliorates T-cell-mediated hepatic injury and s

93 These results indicate that rhIL-11 supports mucous membrane integrity of the alimen

94 iotropic transcription factor indicates that rhIL-11 has therapeutic potential in a wide range of dis

95 These results show that rhIL-11 and DDAVP raise plasma VWF by different mechanis

96 Preclinical data has shown that rhIL-11 limits mucosal injury after chemotherapy and att

97 We have shown that rhIL-11-induced murine and human megakaryocytopoiesis ar

98 This study shows that rhIL-11 treatment of a dose of 50 micrograms/kg signific

99 sable pool of VWF and FVIII, suggesting that rhIL-11 does not significantly alter trafficking of thes

100 The rhIL-11 produced a gradual and sustained elevation of VW

101 rative effect of rhIL-11 indicating that the rhIL-11 activity was not mediated through the induction

102 The effect of continuous exposure to rhIL-11 was accessed by treating wild type mice for 7 co

103 After a short exposure of purified BM MKs to rhIL-11, enhanced phosphorylation of both its signal tra

104 other grade 3 or 4 adverse events related to rhIL-11 were seen.

105 ype mice, vWf heterozygous mice responded to rhIL-11 treatment by a significant increase in platelet

106 Seven of 12 patients responded well to rhIL-11 treatment.

107 In vitro, rhIL-11 did not increase vWf production by cultured endo

108 ycle arrest is a possible mechanism by which rhIL-11 may protect intestinal epithelial cells from dam

109 Most adverse events associated with rhIL-11 were reversible, mild to moderate in severity, a

110 marrow (BM) mononuclear cells cultured with rhIL-11, IL-3, and a combination of the two cytokines.

111 ltured in serum-free fibrin clot medium with rhIL-11, IL-3, or rhIL-11 plus IL-3 and an antibody that

112 Moreover, dogs pretreated with rhIL-11 retain a DDAVP-releasable pool of VWF and FVIII,

113 ouse model of endotoxemia, pretreatment with rhIL-11 blocked LPS-induced elevation of TNF-alpha, IL-1

114 Five of 23 (18%) patients treated with rhIL-11 at 25 micrograms/kg avoided platelet transfusion

115 of 27 (30%) evaluable patients treated with rhIL-11 at a dose of 50 micrograms/kg did not require pl

116 IEC-6 cells treated with rhIL-11 or rhTGF-beta 1 exhibited a reduced proliferativ

117 volved skin before and during treatment with rhIL-11 and was examined by histology/immunohistochemist

118 Short-term treatment with rhIL-11 is well tolerated in patients with active Crohn'

119 Treatment with rhIL-11 significantly reduced the total number of platel

120 Treatment with rhIL-11 with or without DDAVP may provide an alternative